Kindred Biosciences stock exits public markets after Elanco deal
Published on 09/28/2026 at 20:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Kindred Biosciences stock has returned to the headlines through a September 3, 2026 SEC action tied to the company's USD 440 million sale to Elanco. The transaction closed on August 27, 2021 and shifted Kindred into Elanco's wholly owned subsidiary.
SEC action revives the deal
According to Hannah Howell on September 14, 2026, the SEC filed consents on September 3 involving two people who traded Kindred shares before the Elanco announcement. Each agreed to a civil penalty of USD 54,718, subject to court approval.
The case places the historical stock in a current regulatory context rather than a conventional earnings or product cycle. The transaction was announced on June 16, 2021, and the acquisition's completion on August 27, 2021 determined the security's corporate status.
Trading figures show the timeline
The trading activity cited in the case involved 500 Kindred shares purchased by an Elanco employee and 38,000 shares purchased by the recipient of the information. The second position was 76 times larger than the first, a concrete contrast that explains why the transaction remains central to the current filing.
The two trades also produced sharply different outcomes. The employee earned USD 2,447.50, while the second trader earned USD 109,437, according to Hannah Howell on September 14, 2026.
Corporate status changed in 2021
Kindred Biosciences was founded as a companion-animal biotechnology company, but the Elanco transaction changed the investment framework from public-market reporting to ownership within a larger animal-health group. For readers researching KIN, the key date is August 27, 2021, when the acquisition closed and Kindred became wholly owned by Elanco.
Kindred Biosciences reference data
- Company: Kindred Biosciences, Inc.
- ISIN: US4945761006
- Ticker: KIN
- Sector / Industry: Healthcare / biotechnology
